Skip to main content

Advertisement

Table 2 Optimal HIV-derived HLA class I restricted CTL epitopes

From: Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Protein HLA Restriction Sequence Position
gp120 A02 RGPGRAFVTI 311–320
gp120 A03 TVYYGVPVWK 37–46
gp120 A11l SVITQACPK 199–207
gp120 A24 LFCASDAKAY 53–62
gp120 A29 SFEPIPIHY 209–217
gp120 A30 HIGPGRAFY 310–318
gp120 A32 RIKQIINMW 419–427
gp120 B07 RPNNNTRKSI 303–312
gp120 B08 RVKEKYQHL 2–10
gp120 B1516/Cw04 SFNCGGEFF 379–387
gp120 B3801 MHEDIISLW 104–112
gp120 B35 VPVWKEATTTL 42–52
gp120 B35 DPNPQEVVL 77–85
gp120 B44 AENLWVTVY 30–38
gp120 B51 LPCRIKQII 416–424
gp120 B55 VPVWKEATTT 42–51
gp120 A33 VFAVLSIVNR 187–196
gp120 A33 EVAQRAYR 320–327
gp41 A01 RRGWEVLKY 787–795
gp41 A02 SLLNATDIAV 818–827
gp41 A0205 RIRQGLERA 335–343
gp41 A03/A30 RLRDLLLIVTR 775–785
gp41 A23/A24 RYLKDQQLL 591–598
gp41 A30 IVNRNRQGY 704–712
gp41 A30 KYCWNLLQY 794–802
gp41 A6802 IVTRIVELL 782–790
gp41 B07 IPRRIRQGL 843–851
gp41 B08 YLKDQQLL 591–598
gp41 B08 RQGLERALL 848–856
gp41 B14 ERYLKDQQL 589–597
gp41 B2705 GRRGWEALKY 791–799
gp41 B35 TAVPWNASW 611–619
gp41 B4001 QELKNSAVSL 810–819
gp41 Cw3/Cw15 RAIEAQQHL 46–54
p17 A02 SLYNTVATL 77–85
p17 A03 KIRLRPGGK 18–26
p17 A03 RLRPGGKKK 20–28
p17 A03 RLRPGGKKKY 20–29
p17 A11 TLYCVHQRI 84–92
p17 A24 KYKLKHIVW 28–36
p17 A30 RSLYNTVATLY 74–86
p17 B08 GGKKKYKL 24–31
p17 B08 ELRSLYNTV 74–82
p17 B2705 IRLRPGGKK 19–27
p17 B35 WASRELERF 36–44
p17 B35 NSSKVSQNY 124–132
p17 B4001 IEIKDTKEAL 92–101
p17 B4002 GELDRWEKI 11–19
p24 A0207 YVDRFYKTL 164–172
p24 A11 ACQGVGGPGHK 349–359
p24 A24/B44 RDYVDRFFKTL 296–306
p24 A25 QAISPRTLNAW 145–155
p24 B07 SPRTLNAWV 148–156
p24 B07/B42/B81/Cw8 TPQDLNTML 48–56
p24 B07 GPGHKARVL 223–231
p24 B07 HPVHAGPIA 84–92
p24 B08 EIYKRWII 260–267
p24 B08 DCKTILKAL 329–337
p24 B14 DRFYKTLRA 298–306
p24 B1501 GLNKIVRMY 267–277
p24 B18 FRDYVDRFYK 293–302
p24 B2703 RRWIQLGLQK 260–269
p24 B2705 KRWIILGLNK 265–274
p24 B35 NPVPVGNIY 245–253
p24 B35 PPIPVGDIY 254–262
p24 B39 GHQAAMQML 193–201
p24 B4001 SEGATPQDL 176–184
p24 B4002 KETINEEAA 70–78
p24 B4002 AEWDRVHPV 78–86
p24 B44 AEQASQDVKNW 174–184
p24 B44 EEKAFSPEV 28–36
p24 B52 RMYSPTSI 143–150
p24 B53 TPYDINQML 48–56
p24 B53/B57 QASQEVKNW 176–184
p24 B57 ISPRTLNAW 15–23
p24 B57 KAFSPEVIPMF 30–40
p24 B57 TSTLQEQIGW 108–118
p24 B57 KAFSPEVI 30–37
p24 B58 TSTLQEQIGW 108–117
p24 B58 TSTVEEQIQW 108–117
p24 Cw0I VIPMFSAL 36–43
p24 A25 ETINEEAAEW 71–80
p24 A26 EVIPMFSAL 35–43
p15 A02 FLGKIWPSYK 1–10
p15 B14 CRAPRKKGC 42–50
p15 B4001 KELYPLTSL 33–41
p15 B4002 TERQANFL 64–71
Protease A6802/A74 ITLWQRPLV 3–11
Protease A6802 DTVLEEMNL 30–38
Integrase A30 KIQNFRVYY 219–227
Integrase A03/A11 AVFIHNFKRK 179–188
Integrase B1503 RKAKIIRDY 263–271
Integrase B42 VPRRKAKII 260–268
Integrase B57 KTAVQMAVF 173–181
RT A26 ETKLGKAGY 604–612
RT A02 ALVEICTEM 33–41
RT A02 VIYQYMDDL 179–187
RT A02 ILKEPVHGV 309–317
RT A03 ALVEICTEMEK 33–43
RT A03 GIPHPAGLK 93–101
RT A03/A1 1 AIFQSSMTK 158–166
RT A03 QIYPGIKVR 269–277
RT A03 KLVDFRELNK 73–82
RT A03 RMRGAHTNDVK 356–366
RT A11 IYQEPFKNLK 341–350
RT A11 QIIEQLIKK 80–88
RT B51 TAFTIPSI 128–135
RT B57 IVLPEKDSW 244–252
RT B58 IAMESIVIW 375–383
RT B81 LFLDGIDKA 715–723
RT B1503 VTDSQYALGI 651–660
RT A30 KQNPDIVIY 173–181
RT A30 KLNWASQIY 263–271
RT A30 RMRGAHTNDV 356–365
RT A32 PIQKETWETW 392–401
RT B08 GPKVKQWPL 18–26
RT B1501 LVGKLNWASQIY 260–271
RT B1501 IKLEPVHGVY 309–318
RT B35 TVLDVGDAY 107–115
RT B35 VPLDEDFRKY 118–127
RT B35 NPDIVIYQY 175–183
RT B35 HPDIVIYQY 175–183
RT B4001 IEELRQHLL 202–210
RT B42 YPGIKVRQL 271–279
RT B51 EKEGKISKI 42–50
Vpr A02 AIIRILQQL 59–67
Vpr B07/B81 FPRIWLHGL 34–42
Vpr B51 EAVRHFPRI 29–37
Vpr B57 AVRHFPRIW 30–38
Tat A6801 ITKGLGISYGR 39–49
Tat B1503 FQTKGLGISY 38–47
Tat B53 EPVDPRLEPW 2–11
Tat Cw12 CCFHCQVC 30–37
Vif A03 RIRTWKSLVK 17–26
Vif A03 HMYISKKAK 28–36
Vif A03 KTKPPLPSVKK 158–168
Vif B07 HPRVSSEVHI 48–57
Vif B18 LADQLIHLHY 102–111
Vif B57 ISKKAKGWF 31–39
Nef A02 PLTFGWCYKL 136–145
Nef A02 VLEWRFDSRL 180–189
Nef A03/A11 QVPLRPMTYK 73–82
Nef A03/A11 AVDLSHFLK 84–92
Nef A11 PLRPMTYK 75–82
Nef A24 RYPLTFGW 134–141
Nef A33 TRYPLTFGW 133–141
Nef B07 FPVTPQVPLR 68–77
Nef B07 FPVTPQVPL 68–76
Nef B07 TPQVPLRPM 71–79
Nef B07 RPMTYKAAL 77–85
Nef B07 TPGPGVRYPL 128–137
Nef B07 RQDILDLWIY 106–115
Nef B08 WPTVRERM 13–20
Nef B08 FLKEKGGL 90–97
Nef B1501 TQGYFPDWQNY 117–127
Nef B1501 RMRRAEPAA 19–27
Nef B1503 WRFDSRLAF 183–191
Nef B18/B53 YPLTFGWCY 135–143
Nef B2705 RRQDILDLWI 105–114
Nef B35 VPLRPMTY 74–81
Nef A01/A29/837/857 YFPDWQNYT 120–128
Nef B40 KEKGGLEGL 92–100
Nef B42 TPGPGVRYPL 128–137
Nef B53 YPLTFGWCF 135–143
Nef B57 HTQGYFPDWQ 116–125
Nef B57 HTQGYFPDW 116–124
Nef Cw07 RRQDILDLWIY 105–115
Nef Cw7 KRQEILDLWVY 105–115
Nef Cw8 AAVDLSHFL 83–91
Rev A03 ERILSTYLGR 57–66
Rev B57/B58 KAVRLIKFLY 14–23
Rev Cw05 SAEPVPLQL 67–75
Vpu A33 EYRKILRQR 29–37
  1. All epitopes were referred from the Los Alamos HIV Immunology Database 2004 [24].